Showing results (1861-1870 of 2,001) with videos related to

Sort By:
Pageof 201
Space Science Reviews|November 18, 2021
Understanding the Origins of Problem Geomagnetic Storms Associated with "Stealth" Coronal Mass EjectionsNariaki V Nitta, Tamitha Mulligan, Emilia K J Kilpua, et al.
Nutrition Bulletin|April 6, 2021
Learning in lockdown: Using the COVID-19 crisis to teach children about food and climate changeA Kluczkovski, R Lait, C A Martins, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
American Journal of Respiratory and Critical Care Medicine|July 21, 2001
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosisG W Hunninghake, M B Zimmerman, D A Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 27, 2015
Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way ForwardRuth A Roberts, Michael Aschner, David Calligaro, et al.
Plos Genetics|March 21, 2019
A missense variant in FTCD is associated with arsenic metabolism and toxicity phenotypes in BangladeshBrandon L Pierce, Lin Tong, Samantha Dean, et al.
JAMA|October 23, 2003
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialMark G Kris, Ronald B Natale, Roy S Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosisJ J Cook, S J Gardell, M A Holahan, et al.
Pageof 201